HUTCHMED (China) (HMDCF) Beginning Cash Balance (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Beginning Cash Balance came in at $71.3 million in Q2 2026, down 53.67% year-over-year from $154.0 million in Q2 2025, and down 53.67% quarter-over-quarter from $154.0 million in Q2 2025.
Analysis
HUTCHMED (China) (HMDCF) Beginning Cash Balance (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Beginning Cash Balance for 12 consecutive years, with $71.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Beginning Cash Balance fell 53.67% year-over-year to $71.3 million in Q2 2026; TTM through Jun 2026 was $71.3 million, a 53.67% decrease from a year earlier, with the FY2018 full-year figure at $85.3 million, up 7.34% from the prior year.
- Beginning Cash Balance was $71.3 million for Q2 2026 at HUTCHMED (China), down from $154.0 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $377.5 million in Q2 2022 and troughed at $71.3 million in Q2 2026.
- A 5-year average of $239.9 million and a median of $283.6 million in 2024 frame the typical range for Beginning Cash Balance.
- Across the five-year window, Beginning Cash Balance soared 60.23% in 2022 and sank 53.67% in 2026, its largest moves.
- Over 5 years, Beginning Cash Balance stood at $377.5 million in 2022, then slipped by 17.02% to $313.3 million in 2023, then slipped by 9.48% to $283.6 million in 2024, then tumbled by 45.71% to $154.0 million in 2025, then slumped by 53.67% to $71.3 million in 2026.
- The last three Beginning Cash Balance figures came in at $71.3 million (Q2 2026), $154.0 million (Q2 2025), and $283.6 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.93 Bn | 198.94 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.03 Bn | 177.85 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.73 Bn | 124.87 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.26 Bn | 74.27 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.30 Bn | 56.11 Bn | 1.37 Bn |
| 6 | Moderna | 54.88 Bn | 49.75 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn |
| 8 | Biogen | 31.22 Bn | 29.94 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71.33 Mn |
| Jun 30, 2025 | 153.96 Mn |
| Jun 30, 2024 | 283.59 Mn |
| Jun 30, 2023 | 313.28 Mn |
| Jun 30, 2022 | 377.54 Mn |
| Jun 30, 2021 | 235.63 Mn |
| Mar 31, 2021 | 235.63 Mn |
| Jun 30, 2020 | 121.16 Mn |
| Mar 31, 2020 | 121.16 Mn |
| Sep 30, 2019 | 86.04 Mn |
| Jun 30, 2019 | 86.04 Mn |
| Mar 31, 2019 | 86.04 Mn |
| Dec 31, 2018 | 85.27 Mn |
| Sep 30, 2018 | 85.27 Mn |
| Jun 30, 2018 | 85.27 Mn |
| Mar 31, 2018 | 85.27 Mn |
| Dec 31, 2017 | 79.43 Mn |
| Jun 30, 2017 | 79.43 Mn |
| Dec 31, 2016 | 31.94 Mn |
| Jun 30, 2016 | 31.94 Mn |